|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM324328532 |
| 003 |
DE-627 |
| 005 |
20231225190105.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2021.108728
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1081.xml
|
| 035 |
|
|
|a (DE-627)NLM324328532
|
| 035 |
|
|
|a (NLM)33878452
|
| 035 |
|
|
|a (PII)S1521-6616(21)00065-6
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Chen, Ying
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 26.07.2021
|
| 500 |
|
|
|a Date Revised 26.07.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2021 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a OBJECTIVE: To investigate the relationship between lncRNA PVT1(PVT1) level and PD-L1 expression and their functions in cisplatin resistant epithelial ovarian cancer (CREOC)
|
| 520 |
|
|
|a METHODS: PVT1 and PD-L1 in ovarian cancer tissues were detected and analyzed. The cells proliferation, apoptosis, invasion abilities and potential mechanism were detected by cell functional experiments and western-blot assay, respectively
|
| 520 |
|
|
|a RESULTS: The average expressions of PVT1 and PD-L1 in CREOC tissues were significantly higher. The expression of PVT1 is positively associated with PD-L1 in CREOC. Higher expressions of PVT1 and PD-L1 indicated more malignant clinical behavior and shorter PFS and OS. Knockdown of PVT1 inhibited the proliferation and invasion and promote apoptosis for A2780cis cells, which may be related to decrease the expression of PD-L1 via repressing JAK2/STAT3 pathway
|
| 520 |
|
|
|a CONCLUSIONS: The synergistic therapeutic strategy using LncRNA PVT1-targeted therapy and immune checkpoint blockade of PD-L1 warrant study further for ovarian cancer patients with cisplatin resistant recurrence
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Long non-coding RNA
|
| 650 |
|
4 |
|a Ovarian cancer
|
| 650 |
|
4 |
|a PD-L1
|
| 650 |
|
4 |
|a PVT1
|
| 650 |
|
4 |
|a Resistant
|
| 650 |
|
7 |
|a Antibodies, Monoclonal, Humanized
|2 NLM
|
| 650 |
|
7 |
|a Antineoplastic Agents
|2 NLM
|
| 650 |
|
7 |
|a B7-H1 Antigen
|2 NLM
|
| 650 |
|
7 |
|a Immune Checkpoint Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a PVT1 long-non-coding RNA, human
|2 NLM
|
| 650 |
|
7 |
|a RNA, Long Noncoding
|2 NLM
|
| 650 |
|
7 |
|a RNA, Small Interfering
|2 NLM
|
| 650 |
|
7 |
|a STAT3 Transcription Factor
|2 NLM
|
| 650 |
|
7 |
|a atezolizumab
|2 NLM
|
| 650 |
|
7 |
|a 52CMI0WC3Y
|2 NLM
|
| 650 |
|
7 |
|a Janus Kinase 2
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.2
|2 NLM
|
| 650 |
|
7 |
|a Cisplatin
|2 NLM
|
| 650 |
|
7 |
|a Q20Q21Q62J
|2 NLM
|
| 700 |
1 |
|
|a Li, Fangxuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Dan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Wenxin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Lei
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 227(2021) vom: 09. Juni, Seite 108728
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:227
|g year:2021
|g day:09
|g month:06
|g pages:108728
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2021.108728
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 227
|j 2021
|b 09
|c 06
|h 108728
|